Macrogen, Inc. 038290.KQ Stock

Macrogen, Inc. provides genetic and genomic analysis research services in South Korea and internationally. It offers next generation sequencing (NGS) services, such as whole genome, exome, targeted, transcriptome, metagenome, epigenome, and single cell multi-omics sequencing, as well as whole genome resequencing; and standard, difficult template, and 16S/18S/26S rRNA and ITS region sequencing services, as well as animal/plant identification, PCR optimization/amplification, pyrosequencing, NGS validation, multi locus sequence typing analysis, sanger sequencing, primer walking, and cloning services. The company also provides fragment analysis services; clinical diagnostic; personal genome analysis; genetic testing services for research purposes, such as messenger RNA, microRNA, single nucleotide polymorphism, comparative genome hybridization, and DNA methylation; oligo and gene synthesis; and clustered regularly interspaced short palindromic repeats design and synthesis material, gRNA synthesis, validated gRNA, and gRNA plasmid services. In addition, it offers genetically engineered mice for use in biological and medical research to identify the functions of human genes; transgenic mouse in which a specific gene has been inserted to study the function of the gene; and GEM-related services, including mass reproduction, microinjection, mouse line recovery, embryo freezing and reproduction, and KO/TG mouse maintenance. Further, the company provides covid-19 test kit under the Axen name, as well as operates smart mobile lab for covid-19 testing. Additionally, it offers iD4U genetic testing services for kinship and personal identification; and myPETGENE genetic testing service for pets. Macrogen, Inc. was founded in 1997 and is headquartered in Seoul, South Korea.